NCT03055845View on ClinicalTrials.gov

A Single Ascending Dose Study of Safety and Tolerability of STA363 Compared to Placebo in 15 Patients With Chronic Discogenic Low Back Pain

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 27, 2017

Primary Completion Date

August 29, 2019

Study Completion Date

August 29, 2019

Conditions
Low Back Pain
Interventions
DRUG

STA363

STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.

DRUG

Placebo

Matching placebo solution with identical appearance to the test product, used as reference treatment. Administered as intradiscal injection.

Trial Locations (1)

19489

Stockholm Spine Center, Löwenströmska Sjukhuset, Upplands Vasby

Sponsors
All Listed Sponsors
lead

Stayble Therapeutics

INDUSTRY

NCT03055845 - A Single Ascending Dose Study of Safety and Tolerability of STA363 Compared to Placebo in 15 Patients With Chronic Discogenic Low Back Pain | Biotech Hunter | Biotech Hunter